🚀 VC round data is live in beta, check it out!
Magle Chemoswed Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Magle Chemoswed Holding and similar public comparables like Medicofarma Biotech, Futura Medical, Vivesto, Chosa Oncology and more.
Magle Chemoswed Holding Overview
About Magle Chemoswed Holding
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
Founded
2012
HQ
Employees
70
Website
Sectors
Financials (FY)
EV
$46M
Magle Chemoswed Holding Financials
Magle Chemoswed Holding reported last fiscal year revenue of $31M and negative EBITDA of ($3M).
In the same fiscal year, Magle Chemoswed Holding generated $25M in gross profit, ($3M) in EBITDA losses, and had net loss of ($17M).
Revenue (LTM)
Magle Chemoswed Holding P&L
In the most recent fiscal year, Magle Chemoswed Holding reported revenue of $31M and EBITDA of ($3M).
Magle Chemoswed Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $31M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $25M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 82% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (9%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (48%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($17M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (57%) | XXX | XXX | XXX |
| Net Debt | — | — | $34M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Magle Chemoswed Holding Stock Performance
Magle Chemoswed Holding has current market cap of $9M, and enterprise value of $46M.
Market Cap Evolution
Magle Chemoswed Holding's stock price is $0.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $46M | $9M | 0.3% | XXX | XXX | XXX | $-0.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMagle Chemoswed Holding Valuation Multiples
Magle Chemoswed Holding trades at 1.5x EV/Revenue multiple, and (17.2x) EV/EBITDA.
EV / Revenue (LTM)
Magle Chemoswed Holding Financial Valuation Multiples
As of April 19, 2026, Magle Chemoswed Holding has market cap of $9M and EV of $46M.
Equity research analysts estimate Magle Chemoswed Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Magle Chemoswed Holding has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV (current) | $46M | XXX | $46M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (17.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (3.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.8x | XXX | XXX | XXX |
| P/E | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (13.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Magle Chemoswed Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Magle Chemoswed Holding Margins & Growth Rates
Magle Chemoswed Holding's revenue in the last fiscal year grew by 20%.
Magle Chemoswed Holding's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.6M for the same period.
Magle Chemoswed Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (9%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (141%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 130% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Magle Chemoswed Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Magle Chemoswed Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Medicofarma Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Futura Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivesto | XXX | XXX | XXX | XXX | XXX | XXX |
| Chosa Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Magle Chemoswed Holding M&A Activity
Magle Chemoswed Holding acquired XXX companies to date.
Last acquisition by Magle Chemoswed Holding was on XXXXXXXX, XXXXX. Magle Chemoswed Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Magle Chemoswed Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMagle Chemoswed Holding Investment Activity
Magle Chemoswed Holding invested in XXX companies to date.
Magle Chemoswed Holding made its latest investment on XXXXXXXX, XXXXX. Magle Chemoswed Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Magle Chemoswed Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Magle Chemoswed Holding
| When was Magle Chemoswed Holding founded? | Magle Chemoswed Holding was founded in 2012. |
| Where is Magle Chemoswed Holding headquartered? | Magle Chemoswed Holding is headquartered in Sweden. |
| How many employees does Magle Chemoswed Holding have? | As of today, Magle Chemoswed Holding has over 70 employees. |
| Is Magle Chemoswed Holding publicly listed? | Yes, Magle Chemoswed Holding is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Magle Chemoswed Holding? | Magle Chemoswed Holding trades under MAGLE ticker. |
| When did Magle Chemoswed Holding go public? | Magle Chemoswed Holding went public in 2020. |
| Who are competitors of Magle Chemoswed Holding? | Magle Chemoswed Holding main competitors are Medicofarma Biotech, Futura Medical, Vivesto, Chosa Oncology. |
| What is the current market cap of Magle Chemoswed Holding? | Magle Chemoswed Holding's current market cap is $9M. |
| What is the current revenue of Magle Chemoswed Holding? | Magle Chemoswed Holding's last fiscal year revenue is $31M. |
| What is the current EV/Revenue multiple of Magle Chemoswed Holding? | Current revenue multiple of Magle Chemoswed Holding is 1.5x. |
| Is Magle Chemoswed Holding profitable? | No, Magle Chemoswed Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.